Last call for the Hematologic Malignancies Conference. Join Britta Will, Alejandro Gutierrez and speakers, Peggy Goodell and Mark Dawson for 37 invited talks and 18 talks on blood cancers and related science. Registration ends Aug 2. #HMCSRC Reserve your spot now: bit.ly/44pHp5o

A shoutout for our recent study on mechanisms of BH3 mimetics resistance and Mitophagy Cancer Discovery Our lab has fully funded postdoctoral positions to study #mitochondria dynamics & function in drug response! Come join us in New York City! NYU Grossman School of Medicine aacrjournals.org/cancerdiscover…

👉👉👉Check out our group’s paper 📝 Led by Dr .Jayastu Senapati & Dr .Nitin Jain on Ph-like B-ALL out in JCO Precision Oncology ascopubs.org/doi/10.1200/PO… | #leusm #endcancer MD Anderson Cancer Center | Charles Mullighan Hagop Kantarjian,MD 🚨

ボストンきた

Fantastic second day FASEB #HMCSRC! Lots of unpublished data so refraining from posting. Here’s tonight’s lineup of poster presentations.

さらばボストン

留学先を選ぶ際、PIがどれくらいの金額、期間のグラントを持っているか知るのは大事。そこで便利なのがこのサイト。PIの名前を入れると... reporter.nih.gov

✨Cancer Science誌 ハイライト論文紹介✨ 急性骨髄性白血病(AML)細胞のミトコンドリアにおいて　 GPAM発現が亢進し、リゾホスファチジン酸が増加していることが分かった。GPAMはAMLの治療標的になりうる。 onlinelibrary.wiley.com/doi/full/10.11… #AML #ミトコンドリア #GPAM #LPA #治療標的

📢We are currently in search of a new #PI at #IRCMS. Are you interested in conducting research with us in #Kumamoto? Your expertise could make a significant impact! 🧪🧬 #KumamotoUniversity #国際先端医学研究機構 #熊本大学 ircms.kumamoto-u.ac.jp/news/2023/08/p…

The increment of thrombospondin-1, which promotes the multimerization of von Willebrand factor could be associated with IMiDs-induced venous thromboembolisms. ow.ly/qYhZ50Qzl1v #thrombosisandhemostasis

Our paper on the role of the mTOR pathway in dexamethasone resistance in B-ALL cells has just been published in Blood Neoplasia! Congratulations to Hiroshi and thanks to all our collaborators! sciencedirect.com/science/articl…

Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells ashpublications.org/bloodneoplasia…

Online Now: Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas dlvr.it/T6Mr8b

Trial of axi-cel in PCNSL/SCNSL #ASCO24: - 18 pts, no bridging allowed (other than taper dex) - 28% Gr3 ICANS, no Gr4-5 - ORR 94% (CR 67%), mDOR 13 mos - mPFS 14.3, mOS 26.4 Curious about stratification for dx status at time of CAR given poor outcomes with active CNS dx. #lymsm

Cancer after #CART? Drs. Mark Hamilton, Takeshi Sugio, Troy Noordenbos, Ash Alizadeh, MD/PhD 🇺🇸, and David Miklos studied the risk of T cell lymphomas in patients treated with CAR T therapy. 📎 NEJM: bit.ly/3zrDcnb 🎙️: bit.ly/4ePiaPO

Our paper on the biomarker of selinexor (XPO1 inhibitor, FDA approved for R/R MM and DLBCL) sensitivity has been published online in Leukemia (rdcu.be/dNofH). Via CRISPR dropout screens, we found that DDX19 homologue dosage is key for selinexor sensitivity.

nature.com/articles/s4137…

Genome-wide CRISPR/Cas9 screens identify the mTORC1 pathway as crucial for B-ALL cell sensitivity to dexamethasone. ow.ly/324650SMLLq #lymphoidneoplasia #acutelymphocyticleukemia #basicmechanismsofneoplasia

今週🏫11月23日（土）あさ10時30分から 『THE名門校 日本全国すごい学校名鑑』 鹿児島市　ラ・サール学園 ✅毎年約40人が東大合格！ラ・サール教育の秘密 ✅週3回以上のテスト ✅日本語禁止の校舎「英語棟」 ✅毎日3時間の義務自習・○○に行列…約600人が暮らす学生寮へ潜入 #THE名門校 #橋本マナミ

Thrilled to share a wonderful collaboration with Scott Armstrong Florian Perner Shellaina Gordon !! Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia biorxiv.org/content/10.110…